In addition, calcium and calcitriol administration, which is aimed at alleviating hypocalcemia in symptomatic patients, may further exacerbate hypercalciuria, which may subsequently induce nephrocalcinosis, nephrolithiasis, and impaired renal function in patients with ADH1 [17]. This evidence concerns the gene ADH1A and nephrolithiasis.